Watanabe A, Oizumi K, Motomiya M, Yoshida T, Ito T, Kanayama H, Saito J, Nakai Y, Sato K
Department of Internal Medicine, Tohoko University.
Jpn J Antibiot. 1990 May;43(5):768-78.
We evaluated the therapeutic efficacy of ceftibuten (CETB, 7432-S), a new cephem antibiotic for oral use, in chronic respiratory tract infections. A daily dose of 400 mg (b.i.d.: 15 cases) or 600 mg (t.i.d.: 5 cases) of CETB was given orally for 3-14 days (mean: 10.6 days) to 20 patients: 9 with infected bronchiectasis, 3 with infection supervened on pulmonary emphysema, 3 with acute pneumonia (supervened on bronchiectasis in 2 of 3 cases), 2 with infected bronchial asthma, 1 each with infection supervened on old pulmonary tuberculosis, chronic bronchitis and pulmonary fibrosis. The clinical effects were excellent in 3, good in 11, fair in 3 and poor in 3. Eighteen strains were identified as causative organisms. Eight of 15 strains for which bacteriological responses were evaluable were eradicated by the use of CETB. Eosinophilia in 2 patients and an elevation of S-GPT value was observed in 1 patient. These adverse reactions disappeared after the completion of the therapy. From the above results, we conclude that CETB is one of the most useful antibiotics for oral use as a first choice in chronic respiratory tract infections.
我们评估了新型口服头孢烯类抗生素头孢布烯（CETB，7432-S）对慢性呼吸道感染的治疗效果。20例患者口服CETB，每日剂量400mg（bid：15例）或600mg（tid：5例），疗程3 - 14天（平均10.6天）：其中9例为感染性支气管扩张，3例为肺气肿合并感染，3例为急性肺炎（3例中有2例继发于支气管扩张），2例为感染性支气管哮喘，1例为陈旧性肺结核合并感染，1例为慢性支气管炎合并感染，1例为肺纤维化合并感染。临床疗效：优3例，良11例，中3例，差3例。共鉴定出18株病原菌。在可评估细菌学反应的15株菌株中，8株使用CETB后被清除。2例患者出现嗜酸性粒细胞增多，1例患者血清谷丙转氨酶（S-GPT）值升高。这些不良反应在治疗结束后消失。根据上述结果，我们得出结论，CETB是慢性呼吸道感染口服治疗的首选最有效的抗生素之一。
